5 news items
Atossa Therapeutics Announces Support Of New Breast Cancer Screening Guidelines
ATOS
7 May 24
beginning at the age of 40 until the age of 74. The change to the recommended age comes in response to rising breast cancer rates among younger women
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control," said
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control," said
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
of the study agreement, Quantum Leap will conduct the study with Atossa and Eli Lilly and Company each responsible for supplying their respective study
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
ATOS
9 Apr 24
lesion decreases in all patients with one complete response (CR), one partial response (PR) and four stable disease (SD), per Response Evaluation
- Prev
- 1
- Next